Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
In terms of efficacy, after 24 weeks of treatment, the changes in body weight for different doses in the Retatrutide group were: -2.1% for the placebo group, -7.2% for the 1 mg group, -12.9% for the 4 mg group, -17.3% for the 8 mg group, and -17.5% for the 12 mg group
First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant therapy
It also supports hepatic detoxification pathways, improving systemic clearance of toxins and metabolic waste
Visit our Plans & pricing page to learn more
Zepbound and Wegovy are FDA-approved for Obesity, and Mounjaro and Ozempic are FDA-approved for the treatment of type 2 diabetes
Ready to Start Your Wegovy Weight Loss Journey
